Special Issue

Effects of Nanoparticles on Living Organisms

Message from the Guest Editor

This Special Issue aims to examine the effects of nanoparticles on living organisms (human or animal, organs, tissues, and cells). Nanoparticles are used in food, agriculture, drug discovery, and medicine (prevention and diagnosis). For example, in the medical field, it is used as a contrast agent in MRI and PET to reveal the internal structure of blood vessels, organs, and tissues. In the drug discovery field, drugs must be safe and effective and able to be delivered to the target site. Therefore, we need to understand the properties and behavior of nanoparticles. Otherwise, they can cause respiratory and cardiovascular diseases, as well as immunological, inflammatory, and allergic diseases. Here, we call for reports on the effects of nanoparticles on living organisms (nanoparticles functionalization, in vitro/in vivo evaluation, 3D models, ADME, toxicity, and biomedical applications, etc.) at the molecular level. Therefore, the objective of this Special Issue is to publish high-quality articles, including original research, reviews, short communications, and clinical trials.

Guest Editor

Dr. Yoshitaka Miyamoto

Department of Precision Biomedical Engineering, Institute of Biomaterials and Bioengineering, 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan

Deadline for manuscript submissions

closed (31 December 2022)

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/101927

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

mdpi.com/journal/cimb

MDPI

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/cimb

MDPI

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia
Department of Pathology and Molecular Medicine, University of Otago, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.